Effects of Nicotinamide Riboside on Metabolism and Vascular Function

Aging Clinical Trial

Official title:

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03501433
• Other study ID #: 17-603
• Status: Completed
• Phase: N/A
• Start date: February 1, 2018
• Est. completion date: December 1, 2019

Study information

• Verified date: September 2020
• Source: Iowa State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Description:

The purpose of this study is to determine the effects of 7 days of Nicotinamide Riboside (NR) or placebo supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: December 1, 2019
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 18 to 35 (young) and 60 to 75 (older)

• Normo- or pre-hypertensive (blood pressure <140/90 mmHg)

• Non-smokers

• Able to give informed consent and participate in all laboratory visits

Exclusion Criteria:

• Currently taking any medications that could interfere with cardiovascular or metabolic outcomes will be excluded from the study (e.g., beta-blockers)

• Known metabolic (e.g. Type I or Type II diabetes, cardiovascular disease, etc.) or immunologic (e.g. HIV, cancer, autoimmune, etc.) diseases

• Food allergies to egg, milk, soy or wheat

• Women who are pregnant or planning to become pregnant during the course of the study,

• Pacemaker or other implanted device

• Unwilling to participate in the experimental protocol or blood draws will be excluded

Related Conditions & MeSH terms

• Aging
• Hyperlipidemias
• Lipemia

Intervention

Dietary Supplement:
• Nicotinamide riboside chloride (Niagen)
250 mg capsules 2x/day for 7 days
• Placebo
2x/day for 7 days

Locations

Country	Name	City	State
United States	Iowa State University	Ames	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Iowa State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NAD+	Blood and peripheral blood mononuclear cell (PBMC) levels	7 days
Secondary	Vasodilatory responsiveness	Post-Occlusion Reactive Hyperemia (PORH)	7 days
Secondary	Lipdemia	Fasting and postprandial	7 days
Secondary	Oxidative stress and inflammation	Plasma markers and expression in circulating PBMCs	7 days